Molecular Image-guided Targeted Biopsy for Prostate and other Cancer

David M Schuster, MD
Division of Nuclear Medicine and Molecular Imaging
Department of Radiology and Imaging Sciences
Emory University
Disclosures

• Dr. Schuster: No direct COI
  – Participate in Emory University grants including fluciclovine, and $^{99m}$Tc-MIP-1404
  – Research funding: Blue Earth Diagnostics Ltd., Nihon Medi-Physics Co. Ltd; SNMMI-CTN, Progenics

• Emory University and Dr. Mark Goodman
  – Eligible for royalties for Fluciclovine
  – BED provides Fluciclovine cassettes for research

Support: National Institutes of Health (R01CA129356; P50 CA 128301, R01 CA169188, R01 CA156755; R21 CA176684-01), NCI Cancer Imaging Program (CIP/DCIDE), SNMMI, Georgia Cancer Coalition, Nihon Medi-Physics Co Ltd, Blue Earth Diagnostics Ltd.
Interesting research or greater potential?

Let’s look at some patients…
Suspected Hepatocellular Carcinoma in Cirrhosis


Courtesy Umar Mahmood, MGH
Indocyanine Green (ICG)

- Clinically approved OMI agent
- Fluoresces in the near-infrared spectrum
- Localizes with high sensitivity and target-to-background ratios (TBRs) to:
  - hepatocellular carcinomas (HCCs)
  - intrahepatic colorectal cancer (CRC)

Patient given IV ICG 1 day prior. Needle introduced via image guidance toward the lesion.

Intraprocedural optical molecular images demonstrate increased ICG.

Target to background liver  Within target

Courtesy Umar Mahmood, MGH

Immediate confirmation of target
Another patient with suspected recurrent prostate cancer...
Underwent fluciclovine PET in a clinical trial in which patient gets standard TRUS/Bx then targeted biopsy based on PET

Post-Brachytherapy. Nadir 0.74 ng/ml. Rising PSA to 3.55

Uptake only in left base.

No extraprostatic uptake.
Standard 12-Core (4-15): Negative for malignancy with radiation changes.

Targeted Cores (1-3): Gleason 4+3=7

Standard template 12 core biopsies missed the tumor. The fluciclovine targeted cores detected the cancer Gleason 7 (4+3) in the left base lesion.

Underwent salvage cryotherapy. PSA 0.53 (less than nadir).
From the visible to the invisible to the visible...

- Examples of molecular guided biopsy include:
  - PET/SPECT/Optical/mMRI to *eyeball guide* CT or MR directed biopsy
  - Dedicated equipment to biopsy via real-time molecular techniques
    - interventional PET or mMRI suite
  - Fold molecular information into multimodality techniques including advanced EM tracking
Why do it?

- Anatomic biopsy blind to metabolism
- Molecular guidance to most avid lesion
- Avoid necrosis
- Improve true positivity
- Some lesions only visible with molecular imaging
- Steer biopsy to unique metabolic profile
- Research to validate new tracers/agents
Optical
Handheld Imaging Device

A. ICG bandpass filter
   Imaging catheter
   CCD Camera

B. Camera
   Imaging catheter
   Introducer needle
   Laser excitation

Courtesy Umar Mahmood, MGH

Eyeball
Eyeball to Most Avid Site and Avoid Necrosis

Image-guided Biopsy: What the Interventional Radiologist Needs to Know about PET/CT

Katsuhiro Kobayashi, MD, PhD • Peyush Bhargava, MD • Shanker Raja, MD • Farbod Naseri, MD • Hassan A. Al-Balas, MBBS • Darryl D. Smith, MD • Sharad P. George, MD • Meena S. Vij, MD

Positron emission tomography (PET)/computed tomography (CT) with fluorine 18 fluorodeoxyglucose (FDG) is increasingly used in evaluation of oncology patients. Because PET/CT can demonstrate malignancy before morphologic changes are evident, application of PET/CT information to image-guided biopsy can facilitate early histologic diagnosis and therapy. However, because FDG uptake can be affected by inflammation, it is important to avoid necrosis.

Fusion to biopsy CT
In house software to register CT for FNA with PET/CT

• Smaller distance of needle tip to hottest focus and higher SUVmax at tip corresponded to highest TP vs FN

Metabolic PET/CT-Guided Lung Lesion Biopsies: Impact on Diagnostic Accuracy and Rate of Sampling Error

Ludmila Guralnik\textsuperscript{1,}, Radu Rozenberg\textsuperscript{1,}, Alex Frenkel\textsuperscript{2,}, Ora Israel\textsuperscript{2,3,}, and Zohar Keidar\textsuperscript{2,3}

\textsuperscript{1}Department of Radiology, Rambam Health Care Campus, Haifa, Israel; \textsuperscript{2}Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel; and \textsuperscript{3}B & R Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel

Percutaneous CT-guided fine-needle aspiration (FNA) is routinely used for lung lesions and is a relatively safe method for diagnosis of benign and malignant processes (1). The diagnostic accuracy of CT-guided FNA for malignant lung tumors varies between 64% and 97% (2), depending on factors such as the size and depth of the lesion and the number of needle paths (1, 2). 18F-FDG imaging provides information on the metabolic characteristics of lung lesions (3). Its inherent advantages include early detection of malignancy and differentiation from nonmalignant.

Fusion to ultrasound with EM receiver on US probe
Advantages of percutaneous abdominal biopsy under PET-CT/ultrasound fusion imaging guidance: a pictorial essay

Francesco Paparo, Riccardo Piccazzo, Luca Cevasco, Arnoldo Piccardo, Francesco Pinna, Fiorenza Belli, Lorenzo Bacigalupo, Ennio Biscaldi, Giovanni De Caro, Gian Andrea Rollandi

1Department of Radiology, E.O. Ospedali Galliera, Mura della Cappuccine 14, 16128 Genoa, Italy
2School of Radiology, University of Genoa, Via Leon Battista Alberti 4, 16132 Genoa, Italy
3Nuclear Medicine Unit, E.O. Ospedali Galliera, Mura della Cappuccine 14, 16128 Genoa, Italy
4Unit of Interventional Radiology, E.O. Ospedali Galliera, Mura della Cappuccine 14, 16128 Genoa, Italy
5Department of General and Hepatobiliary Surgery, E.O. Ospedali Galliera, Mura della Cappuccine 14, 16128 Genoa, Italy

Fusion to CT with EM tracking system under CT guidance
Real-time FDG PET Guidance during Biopsies and Radiofrequency Ablation Using Multimodality Fusion with Electromagnetic Navigation

Purpose:
To assess the feasibility of combined electromagnetic device tracking and computed tomography (CT)/ultrasonography (US)/fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) fusion for real-time feedback during percutaneous and intraoperative biopsies and hepatic radiofrequency (RF) ablation.

Materials and Methods:
In this HIPAA-compliant, institutional review board-approved prospective study with written informed consent, 25 patients (17 men, eight women) underwent 33 percutaneous and three intraoperative biopsies of 36 FDG-avid targets between November 2007 and August 2010. One patient underwent biopsy and RF ablation of an FDG-avid
Interventional (Dedicated) PET-CT
Dedicated system (short breath hold PET acquisitions)

**Interventional Molecular Imaging**

Stephen B. Solomon¹ and Francois Corneli²

¹Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and ²Department of Radiology, Pellegrin Hospital, Bordeaux, France

Although molecular imaging has had a dramatic impact on diagnostic imaging, it has only recently begun to be integrated into interventional procedures. Its significant impact is attributed to its ability to provide noninvasive, physiologic information that supplements conventional morphologic imaging. The four major interventional opportunities for molecular imaging are, first, to provide guidance to localize a target; second, to provide tissue analysis to confirm that the target has been reached; third, to provide in-room, posttherapy assessment; and fourth, to deliver targeted therapeutics. This article will provide an update on the status of interventional molecular imaging.

Work at Emory
anti-1-amino-3-[^18F]fluorocyclobutane-1-carboxylic acid (anti-3-[^18F]FACBC)

- Non-natural alicyclic amino acid PET radiotracer
  - developed at Emory
- Fluciclovine not metabolized

Fluciclovine ([^18F])
FDA approved: Axumin

\( ^{18}\text{F} \) radiolabel for PET imaging
Amino terminus
Cyclic side-chain
Carboxy terminus
Early experience

- We had some cases where fluciclovine was positive but biopsy negative
  - yet later proven to have tumor in prostate
- We realized there was non-specificity but also sampling error
  - tease out both elements
    - Approached by Baowei Fei to see if interest in working on a molecular guided ultrasound biopsy system
TRUS-guided Biopsy

12-Core Biopsy
Current Problems

• Two-dimensional (2D) image guidance
  – difficult to go to the same location for re-biopsy in a follow up examination

• Ultrasound imaging has a low sensitivity for detecting cancer
  – essentially blind biopsy
Ongoing Work with Multimodality TRUS Fusion

- UCLA, NCI, others
- Most with MR-TRUS
- NCI ongoing work with PET-MR-TRUS
- Most work in primary or active surveillance setting

Gleason 4+5 DCFBC mpMR with 2 negative prior biopsies

P. Choyke, B. Turkbey, NCI, NIH, Bethesda, MD, USA
Emory - Targeted Biopsy

Molecular Imaging with PET/CT or MRI/MRSI

PET/CT MRI/MRSI 3D Visualization

Real-time 3D ultrasound-guided biopsy

Registration Fusion Visualization

Segmentation Planning Biopsy

3D Ultrasound for real time guidance

NIH R01CA156775, R21CA176684, PI: Baowei Fei
Once we get the 3D images, we can segment the prostate and build a 3D model of the organ.
To incorporate PET-CT into ultrasound guided biopsy, we use CT as the bridge.

If register CT with ultrasound, also able to register PET with ultrasound.
Clinical Setup for Biopsy
Targeted Biopsy in Patients
Clinical Trial

- Suspected recurrence with “intact” prostate
  - non-prostatectomy
- Fluciclovine PET-CT
  - Manually draw regions including prostate
    - *working to automate this process*
- Patients get planning ultrasound before or after PET
Clinical Trial

- Next session undergoes 12 core template biopsy
  - Locations of the 12 cores are randomly generated by the computer according to the template
    - Urologist does not pick the locations of the 12 cores and blinded to targeted lesions
  - Then target lesions are revealed
Clinical Trial

- Standard 12-core biopsy only has a 7% positivity – 1 in 12 cores is positive.
- In our preliminary study of 39 patients (primary and recurrent), our MRI/TRUS fusion biopsy improved the detection rate to 29.3% (27 of 92 cores).
- For our 10 patients with positive lesions on PET, our PET/ultrasound targeted biopsy further improved the detection rate to 60% (9 of 15 targeted cores).
Molecular Guidance

- Direct needle to lesion with confidence and document location
- Determine if lesion outside of normal local field such as seminal vesicle
- Help completely stage the patient before considering salvage therapy
Post local therapy.
Positive fluciclovine in prostate with negative biopsy x 2 in past (deemed FP).
Now PSA rising to 17.8ng/ml.

3rd fluciclovine on peripheral ADT.

Uptake in right posterior base and less so in left anterior base.
Equivocal apex.

But now we had guided biopsy…
Standard TRUS: Negative “treatment effect”
PET guided: Positive in right posterior and left anterior base. Negative in apex.
Molecular Guidance

• Direct needle to lesion with confidence and document location
• Determine if lesion outside of normal field such as seminal vesicle
• Help completely stage the patient before considering salvage therapy
HIFU and subsequent recurrence treated with salvage cryotherapy. Now rising PSA to 4.3 ng/ml.

Fluciclovine PET: Positive in right base/SV and higher up in left SV
Urologist can direct biopsies to SVs
Molecular Guidance

- Direct needle to lesion with confidence and document location
- Determine if lesion outside of normal field such as seminal vesicle
- Help completely stage the patient before considering salvage therapy
PSA recurrence after proton therapy. Fluciclovine 2 years earlier with uptake in right SV (and negative MR), but elected no biopsy or therapy. Now PSA 18.8. Bone scan and mpMR negative.

Right SV hotter.
PSA recurrence after proton therapy. Bone scan and mpMR negative.

But new pelvic and retroperitoneal nodes.
From the visible to the invisible to the visible...

<table>
<thead>
<tr>
<th></th>
<th>Availability</th>
<th>Expense</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyeball</td>
<td>Widely</td>
<td>Least</td>
<td>Least</td>
</tr>
<tr>
<td>Dedicated</td>
<td>Limited</td>
<td>Most</td>
<td>Highest</td>
</tr>
<tr>
<td>Multimodality</td>
<td>Mostly</td>
<td>Modest</td>
<td>High</td>
</tr>
</tbody>
</table>
Future Plans

• Continue to work on technique and workflow
  – Especially automation
    • *e.g. line up brachytherapy seeds*
  – May be great application for PET-MR
• Use data to refine criteria for positivity in bed
• Plan to incorporate other radiotracers such as PSMA
• Active surveillance trial
  – perhaps combination of radiotracers
## Entire Collaborative Team

### Nuclear Medicine/Radiology
- Mark M Goodman PhD
- Bowei Fei, PhD
- Raghu Halkar, MD
- Bital Savir-Baruch MD
- Madge Bellamy, RN
- Rianot Amzat MD
- Pooneh Taleghani MD
- Oluwaseun Odewole, MBBS
- Funmilayo Tade MD, MPH
- Oladunni Olufunmilola Akin- Akintayo, MD MPH
- Oyeladun A. Oyenuga MD, MPH
- Wanzhen Zeng, MD
- Julio Sepulveda, MD
- Jonathon A Nye PhD
- John R Votaw PhD
- Ron Crowe, BCNP and entire Cyclotron Team
- Weiping Yu, PhD
- Fenton Ingram, RT(R), CNMT, PET
- Seraphinah Lawal, RT(R), CNMT, PET
- Nashwa Jarkas, PhD

### Urology
- Peter T Nieh MD
- Viraj Master MD PhD
- Mehrdad Alemozaffar, MD
- Muta Issa, MD
- Bev Hunter, RN

### Radiation Oncology
- Ashesh Jani, MD
- Pete Rossi, MD
- Tim Fox, PhD
- Eduard Schreibmann, PhD

### Medical Oncology
- Omer Kucuk, MD
- Wayne Harris, MD

### Pathology
- Adeboye Osunkoya, MD
- Melinda Lewis, MD
- Carlos Moreno, MD
- Andy Young, MD

### Biostatistics
- F Dubois Bowman PhD
- Nelson Chen, PhD

### Collaborators at:
- University of Bologna
- National Cancer Institute
- Kitasato University School of Medicine
- Uppsala University
- Oslo University Hospital
- Aleris Helse Medical Center Oslo
- Aarhus University Hospital
- Docrates Cancer Center
- Blue Earth Diagnostics, Ltd
- Nihon Medi-Physics Co., Ltd.
- SNMMI CTN
  - Bonnie Clarke
- NIH/NCI
  - Pete Choyke
  - Baris Turkbey
  - Study Sections
- DCIDE Program
  - Paula Jacobs